Compounds > wy 48252
Page last updated: 2024-11-06

wy 48252

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Wy 48252: leukotriene D4 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60539
CHEMBL ID17344
SCHEMBL ID38043
MeSH IDM0158179

Synonyms (27)

Synonym
ritolukast
wy-48252
111974-60-8
ritolukast (usan/inn)
D02849
wy 48252
AKOS000278710
1,1,1-trifluoro-n-[3-(quinolin-2-ylmethoxy)phenyl]methanesulfonamide
CHEMBL17344 ,
c,c,c-trifluoro-n-[3-(quinolin-2-ylmethoxy)-phenyl]-methanesulfonamide
c,c,c-trifluoro-n-[3-(quinolin-2-ylmethoxy)-phenyl]-methanesulfonamide(wy-48,252)
c,c,c-trifluoro-n-[3-(quinolin-2-ylmethoxy)-phenyl]-methanesulfonamide( wy-48,252)
c,c,c-trifluoro-n-[3-(quinolin-2-ylmethoxy)-phenyl]-methanesulfonamide(wy 48252)
bdbm50006806
0e8r4gde2q ,
methanesulfonamide, 1,1,1-trifluoro-n-(3-(2-quinolinylmethoxy)phenyl)-
unii-0e8r4gde2q
1,1,1-trifluoro-alpha-2-quinolylmethanesulfon-m-anisidide
ritolukast [usan:inn]
ritolukastum
ritolukastum [inn-latin]
ritolukast [usan]
ritolukast [inn]
SCHEMBL38043
n-[3-[(2-quinolinyl)methoxy]phenyl]trifluoromethane sulfonamide
DTXSID90149795
Q27236668
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)3.30000.00462.018210.0000AID103805; AID7070
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)IC50 (µMol)6.20000.00291.786810.0000AID160874; AID161013
Platelet-activating factor acetylhydrolaseHomo sapiens (human)IC50 (µMol)2.00000.00000.38373.9000AID103805
Cysteinyl leukotriene receptor 1Cavia porcellus (domestic guinea pig)Ki0.03500.00010.23581.5000AID55065
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)IC50 (µMol)6.20000.00291.823210.0000AID160874; AID161013
Cysteinyl leukotriene receptor 2Homo sapiens (human)Ki0.03500.00020.94296.2000AID55237
Cysteinyl leukotriene receptor 1Homo sapiens (human)Ki0.03500.00021.56248.8720AID55237
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
peptide hormone processingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particle remodelingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
lipid oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
plasma lipoprotein particle oxidationPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phosphatidylcholine catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor metabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of inflammatory responsePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
platelet activating factor catabolic processPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
positive regulation of monocyte chemotaxisPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
1-alkyl-2-acetylglycerophosphocholine esterase activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
phospholipid bindingPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
hydrolase activity, acting on ester bondsPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
calcium-independent phospholipase A2 activityPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionPlatelet-activating factor acetylhydrolaseHomo sapiens (human)
low-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
high-density lipoprotein particlePlatelet-activating factor acetylhydrolaseHomo sapiens (human)
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID77371Relative inhibitor potency of the intraduodenally administered compound with Wy-48,252 against ovalbumin induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID160874Concentration for 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by Prostaglandin G/H synthase1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID140620The compound was tested for inhibitory activity which inhibits prostaglandin E2[PGE2] synthesis by zymosan-activated mouse peritoneal macrophages1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID76998Inhibitory dose of the intragastrically administered compound (120 min before giving agonist) that produced a 50% inhibition of leukotriene D4 induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID161013Inhibitory concentration to inhibit Prostaglandin G/H synthase in the rat1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID76995Inhibitory dose of the intraduodenally administered compound (10 min before giving agonist) that produced a 50% inhibition of leukotriene D4 induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID77372Relative inhibitor potency of the intragastrically administered compound with Wy-48,252 against leukotriene D4 induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID180659The compound was tested for inhibitory activity against synthesis of immunoreactive thromboxane B2 in rat PMNs1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID76976Inhibition of leukotriene D4 induced bronchoconstriction in anesthetized guinea pigs after intravenous administration1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.
AID103805Concentration for 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID79847Compound was tested for LTD4 guinea pig trachea contraction.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID180658The compound was tested for inhibitory activity against synthesis of immunoreactive LTB41992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID76444Inhibition of ovalbumin-induced bronchoconstriction when compound was administered intraduodenally at a dose of 10 mg/kg in guinea pig1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID102661Binding studies using tritium-labelled leukotriene D41989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID76430Inhibition of leukotriene D4 induced bronchoconstriction in anesthetized guinea pigs after aerosol administration as 1% solution; NT means not tested1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.
AID77369Relative inhibitor potency of the intraduodenally administered compound with Wy-48,252 against leukotrien D4 induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID76447Inhibition of ovalbumin-induced bronchoconstriction when compound was administered perorally at a dose of 25 mg/kg in guinea pig1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID55065Binding affinity against Cysteinyl leukotriene D4 receptor from guinea pig lung was determined using [3H]LTD41990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 2. Effects of an additional phenyl ring on receptor affinity.
AID23090Dissociation constant was determined In vitro in isolated guinea pig trachea after intraduodenal administration1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID79839Antagonistic activity against LTD4 induced contraction in guinea pig trachea1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Peptide leukotrienes: current status of research.
AID77097In vitro inhibition of LTD4-induced bronchoconstriction after intragastrical administration 120 min before agonist into isolated guinea pig trachea1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID55054Inhibitory activity to block binding of [3H]leukotriene D4 to LTD4 receptor sites in homogenized guinea pig lung at 10 uM1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.
AID134182Compound was administered intragastrically and tested in a mouse ear edema assay; Inactive1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID54903Inhibitory activity to block binding of [3H]leukotriene D4 to LTD4 receptor sites in homogenized guinea pig lung1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.
AID14020Oral bioavailability was determined; range 49-102%1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID25086Dissociation constant was determined1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID76996Inhibitory dose of the intraduodenally administered compound (10 min before giving agonist) that produced a 50% inhibition of ovalbumin induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID77091Examined in vitro for LTD4-induced bronchoconstriction in isolated guinea pig trachea by injecting intraduodenally1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID55072Compound was evaluated for its ability to displace [3H]LTD4 from LTD4 receptor in guinea pig lung membranes1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Peptide leukotrienes: current status of research.
AID19125Plasma half-life was determined; 0.5-17.7h1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID77101In vitro inhibition of ovalbumin-induced bronchoconstriction after intragastrical administration 120 min before agonist into isolated guinea pig trachea1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID76433Inhibition of leukotriene D4 induced bronchoconstriction in anesthetized guinea pigs after intravenous administration at a dose of 10 mg/kg1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.
AID7070Inhibitory concentration to inhibit 5-lipoxygenase in the rat1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID76254Inhibition of Leukotriene D4 induced bronchoconstriction when compound was administered perorally at a dose of 25 mg/kg in guinea pig1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID77096In vitro for inhibition of ovalbumin-induced bronchoconstriction in isolated guinea pig trachea by injecting intraduodenally1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides. Potent orally active leukotriene D4 antagonists of novel structure.
AID193108The compound was tested for inhibition in rat carrageenan paw edema assay1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID77122The inhibitory dose for antigen induced bronchoconstriction in guinea pig after peroral administration1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID76999Inhibitory dose of the intragastrically administered compound (120 min before giving agonist) that produced a 50% inhibition of ovalbumin induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID77373Relative inhibitor potency of the intragastrically administered compound with Wy-48,252 against ovalbumin induced bronchoconstriction in guinea pigs1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID80628The compound was tested for blocking of LTD4-induced contractions of guinea pig trachea1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID55237Binding affinity against Cysteinyl leukotriene D4 receptor1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID132860The compound was tested for inhibitory activity which inhibits LTC4 synthesis by zymosan-activated mouse peritoneal macrophages1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID183975Compound at 100 mg/kg was administered intragastrically and tested in a rat carrageenan paw edema assay1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID75651Activity against leukotriene D4-induced contraction of guinea pig trachea, in the presence of glutathione1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
AID76252Inhibition of Leukotriene D4 induced bronchoconstriction when compound was administered intraduodenally at a dose of 25 mg/kg in guinea pig1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
N-[(arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene D4 antagonists of novel structure.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (46.67)18.7374
1990's8 (53.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
histamine
[no description available]		2.3820aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
aa 861
2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone: structure given in first source. docebenone : A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group.		3.08101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
theophylline
[no description available]		1.9710dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		1.9710monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.6630aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.		5.5390acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		3.0810catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		1.9810inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		420chromones
pf 5901
alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist		420quinolines
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist		420carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		1.9710indazole
bw-755c
4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine: A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia.		3.0810
dazoxiben
dazoxiben: RN given refers to parent cpd		1.9710
lonapalene
RS 43179: used in treatment of psoriasis		3.0810naphthalenes;
organochlorine compound
ablukast
[no description available]		4.2830
tepoxalin
tepoxalin : A hydroxamic acid obtained by formal condensation of the carboxy group of 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]propanoic acid with the amino group of N-methylhydroxylamine. It is used in veterinary medicine for the control of pain and inflammation caused by musculoskeletal disorders such as hip dysplasia and arthritis in dogs.		3.0810aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles		antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
zileuton
[no description available]		4201-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
pobilukast
pobilukast: a leukotriene receptor antagonist; an antiasthmatic agent; structure in first source; RN refers to (R-(R*,S*)-isomer		420
masoprocol
Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.		1.9810nordihydroguaiaretic acidantineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite
cv 6504
CV 6504: structure given in first source		3.0810
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors		5.1760aromatic ketone
sc 41930
SC 41930: leukotriene B4 receptor antagonist; structure in first source		3.0910
ici 198615
ICI 198615: an LTD4 receptor antagonist; SRS-A antagonist; structure given in first source		3.7630
l 648051
L 648051: antagonist of leukotriene D4 receptor; structure in first source		4.2830
ly 255283
LY 255283: structure given in UD; leukotriene B4 antagonist		3.0910aromatic ketone
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;		3.0910
sk&f 102081
5-(2-dodecylphenyl)-4,6-dithianonanedioic acid: RN & structure in first source; leukotriene receptor antagonist		1.9710
sk&f 102922
5-(2-(8-phenyloctyl)phenyl)-4,6-dithianonanedioic acid: RN & structure in first source; leukotriene receptor antagonist		1.9710
ly 163443
LY 163443: structure in first source; leukotriene receptor antagonist		3.0710
sc 39070
SC 39070: structure in first source; leukotriene D4 antagonist		3.0710
sr 2640
SR 2640: leukotriene D4 and E4 antagonist		4.8440quinolines
ym 16638
YM 16638: structure in first source; leukotriene D4 receptor antagonist		3.0710
rg 12525
RG 12525: leukotriene D4 antagonist; structure in first source		4.8440
wy 45911
Wy 45911: a leukotriene antagonist with lipoxygenase inhibiting activity; structure given in UD		3.7630
ly 203647
LY 203647: structure in first source; leukotriene D4 and E4 receptor antagonist		3.0710
eth 615
ETH 615: leukotriene B4 and interleukin-8 antagonist; structure in first source		3.0810
ici d2138
ICI D2138: structure given in first source; inhibitor of leukotriene B4 synthesis		3.0910
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		3.0810methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
2-(phenylmethyl)-1-naphthol
2-(phenylmethyl)-1-naphthol: structure in UD		3.0810
ly 293111
LY 293111: a leukotriene B4 receptor antagonist; structure given in first source		3.0910aromatic ether
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2h-1-benzopyran-2-propanoic acid
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid: structure in first source; inhibits leukotriene B4 receptors		3.0910
arachidonic acid
icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.		1.9710icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
via 2291
atreleuton: structure given in first source		3.0910
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		1.9710
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.		420aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
leukotriene c4
Leukotriene C4: The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene C4 : A leukotriene that is (5S,7E,9E,11Z,14Z)-5-hydroxyicosa-7,9,11,14-tetraenoic acid in which a glutathionyl group is attached at position 6 via a sulfide linkage.		1.9810leukotrienebronchoconstrictor agent;
human metabolite;
mouse metabolite
thromboxane a2
Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.		1.9810epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
leukotriene e4
Leukotriene E4: A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene E4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).		1.9810amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol
montelukast
montelukast: a leukotriene D4 receptor antagonist		3.0910aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
l 660,711
[no description available]		3.4820quinolines
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)		1.9810
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.3820cysteiniumfundamental metabolite
sb 201993
(E)-3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid: structure given in first source; a competitive LTB(4) receptor antagonist		3.0910
cinalukast
cinalukast: structure given in first source; orally active LTD4 antagonist; an anti-asthmatic agent. cinalukast : 2,2-Diethylsuccinanilic acid substituted at a meta- position by an (E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl group. It selectively antagonizes leukotriene D4 at the cysteinyl leukotriene receptor, in the human airway, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. It is used in the treatment of asthma.		3.07101,3-thiazoles;
carboxylic acid		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
bwa 4c
[no description available]		420
ono 4057
ONO-LB 457: LTB4 receptor antagonist; structure given in first source		3.0910
tmk 688
TMK 688: structure given in first source		3.0810
ticolubant
Ticolubant: a leukotriene B4 antagonist		3.0910
bay x 7195
BAY x 7195: structure given in first source		3.0910
ly 223982
LY 223982: RN & structure in first source; leukotriene B4 antagonist		3.0910
cp 105696
CP 105696: a leukotriene B4 receptor antagonist; structure in first source		3.0910
mk 0571
[no description available]		3.0910
chiniofon
Hydroxyquinolines: The 8-hydroxy derivatives inhibit various enzymes and their halogenated derivatives, though neurotoxic, are used as topical anti-infective agents, among other uses.		3.5890
ConditionIndicatedRelationship StrengthStudiesTrials
Asthma, Bronchial
[description not available]		03.2920
Innate Inflammatory Response
[description not available]		03.5830
Disease, Pulmonary
[description not available]		02.8910
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		03.2920
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		03.5830
Lung Diseases
Pathological processes involving any part of the LUNG.		02.8910
Bronchospasm
[description not available]		02.3820
Anasarca
[description not available]		02.3820
Bronchial Spasm
Spasmodic contraction of the smooth muscle of the bronchi.		02.3820
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.3820
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.8940
Constriction, Pathological
[description not available]		01.9710
Constriction, Pathologic
The condition of an anatomical structure's being constricted beyond normal dimensions.		01.9710
Pulmonary Hypertension
[description not available]		01.9810
Group A Strep Infection
[description not available]		01.9810
Hypertension, Pulmonary
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.		01.9810
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		01.9810